| Product Unit Size | Cost | Quantity | Stock |
|---|
Silodosin is a selective α1A-adrenergic receptor antagonist clinically used to treat benign prostatic hyperplasia/low urinary tract syndrome (BPH/LUTS). Silodosin improves bladder function and blood flow in ischemic conditions in animal models. Additionally, silodosin alters transcriptional regulation through its effect on α-adrenergic receptors, preventing NE-induced inhibition of EIk1 and SRF in the prostate.
| Cas No. | 160970-54-7 |
|---|---|
| Purity | ≥98% |
| Formula | C25H32F3N3O4 |
| Formula Wt. | 495.53 |
| Chemical Name | 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2, 2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2, 3-dihydroindole-7-carboxamide |
| IUPAC Name | 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2, 2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2, 3-dihydroindole-7-carboxamide |
| Synonym | KAD 3213, KMD 3213 |
| Appearance | Yellow to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Yamaguchi K, Aoki Y, Yoshikawa T, et al. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial. Int J Urol. 2013 Jun 3. [Epub ahead of print]. PMID: 23731168.
Goi Y, Tomiyama Y, Nomiya M, et al. Effects of silodosin, a selective α1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction. J Urol. 2013 Sep;190(3):1116-22. PMID: 23545103
Hennenberg M, Strittmatter F, Beckmann C, et al. Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle. PLoS One. 2012;7(11):e50904. PMID: 23226423.